ロード中...
Developing EZH2 Targeted Therapy for Lung Cancer
Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown anti-tumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinomas models expressing high levels of EZH2 (1).
保存先:
| 出版年: | Cancer Discov |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5012289/ https://ncbi.nlm.nih.gov/pubmed/27587466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0800 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|